Operating
D&A
Vertex Pharmaceuticals D&A increased by 0.4% to $55.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.5%, from $48.40M to $55.90M. Over 4 years (FY 2021 to FY 2025), D&A shows an upward trend with a 13.7% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
Higher levels indicate significant capital investment in infrastructure or acquisitions, while lower levels may suggest aging assets or limited capital expenditure.
Detailed definition
This represents the non-cash expense allocated to the cost of tangible and intangible assets over their useful lives. Be...
Peer comparison
High in capital-intensive industries like manufacturing and healthcare devices; lower in service-based sectors.
Metric ID:
depreciation_and_amortization_cfHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $31.30M | $31.70M | $33.80M | $35.90M | $37.30M | $36.70M | $38.40M | $38.80M | $41.40M | $42.10M | $59.00M | $53.50M | $54.00M | $53.20M | $46.50M | $48.40M | $51.70M | $54.00M | $55.70M | $55.90M |
| QoQ Change | — | +1.3% | +6.6% | +6.2% | +3.9% | -1.6% | +4.6% | +1.0% | +6.7% | +1.7% | +40.1% | -9.3% | +0.9% | -1.5% | -12.6% | +4.1% | +6.8% | +4.4% | +3.1% | +0.4% |
| YoY Change | — | — | — | — | +19.2% | +15.8% | +13.6% | +8.1% | +11.0% | +14.7% | +53.6% | +37.9% | +30.4% | +26.4% | -21.2% | -9.5% | -4.3% | +1.5% | +19.8% | +15.5% |
Range$31.30M – $59.00M
CAGR+13.0%
Avg YoY Growth+14.5%
Median YoY Growth+15.1%
Current Streak5 quarters growth
D&A at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's d&a?
- Vertex Pharmaceuticals (VRTX) reported d&a of $55.90M in Q1 2026.
- How has Vertex Pharmaceuticals's d&a changed year-over-year?
- Vertex Pharmaceuticals's d&a increased by 15.5% year-over-year, from $48.40M to $55.90M.
- What is the long-term trend for Vertex Pharmaceuticals's d&a?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's d&a has grown at a 13.7% compound annual growth rate (CAGR), from $125.60M to $209.80M.
- What does d&a mean?
- The non-cash accounting expense for the wear and tear or expiration of assets.